Issue of shares to Mayo Clinic

RNS Number : 6645H

IQ-AI Limited

04 December 2020

 

IQ-AI Ltd

("IQ-AI" or the "Company")

Issue of shares to Mayo Clinic

Further to the announcement dated 9 November 2020, IQ-AI announces the allotment of 282,460 of ordinary shares in IQ-AI to Mayo Clinic at 13.21p per ordinary share (the "New Ordinary Shares"). The New Ordinary Shares were issued in accordance with the research and collaboration agreement regarding IB Trax between Mayo Clinic and Imaging Biometrics, LLC ("IB"), a subsidiary of IQ-AI.

An application has been made for the 282,460 New Ordinary Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and that dealing in the New Ordinary Shares will commence on or around 8am on 8 December 2020. The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.

Following Admission, the Company will have 160,805,109 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 160,805,109.

The above figure of 160,805,109 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

IQ-AI Limited Trevor Brown/Vinod Kaushal/Qu Li Tel: [phone]

Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: [phone]

ABOUT Imaging Biometrics , LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com .

 

END

 

 

IOEFLFSRFTLSIII